Mumbai, XXX: Pune-based technology-oriented biotechnology company Enzene Biosciences Ltd. has announced that it has begun commercial supplies of Adalimumab for treating Ankylosis Spondylitis (AS) and Rheumatoid Arthritis (RA). This is the company’s fourth Biosimilar launch in recent times and the company believes that this first commercial launch using continuous manufacturing technology will help in reducing the cost of RA treatment for millions of patients across India.
Biosimilar medicines have an important role to play in increasing the affordability of treatments for various serious conditions such as cancer, rheumatoid arthritis, osteoporosis, etc. However, conventional biologics manufacturing process is extremely cost intensive, and despite the availability of biosimilars the access to these medicines still remains limited due to their high cost. Enzene is one of the first movers globally in developing a fully-connected continuous manufacturing™ platform . The company claims that their biosimilars can further disrupt the affordability barrier as their novel platform offers several times higher volumetric productivity than conventional manufacturing processes.
According to Dr. Himanshu Gadgil, CEO at Enzene Biosciences, “We have been working on this novel fully integrated platform for the last six years and the commercialisation of Adalimumab is a validation of our innovation-based work culture. Enzene is planning to expand global access of this platform through our CDMO vertical.
Adalimumab development included a comparative efficacy and safety studies in patients with Ankylosing spondylitis, also known as Marie-Strumpell disease or Bechterew’s disease. This is the fourth Biosimilar launch for the company in the last eighteen months.
Mr Sandeep Singh, MD of Alkem Laboratories, said “We have invested significantly in building a world class biotech company through Enzene and our confidence has been justified by series of Biosimilars launches in recent past. Alkem has also built exceptional capabilities in clinical development of complex therapies which has put us in a position to significantly impact Indian healthcare.”
About Enzene Biosciences Ltd:
Enzene is an innovation-driven biotech company a subsidiary of Alkem Laboratories Ltd. (one of the top five pharmaceutical companies in India*) located in Pune, India. Enzene’s focus lies in producing biosimilars, novel biologics, synthetic peptides and phytopharmaceuticals. Enzene also offers a range of biologics CDMO and CMO services with capabilities from clone development up to GMP manufacturing supported by bioreactor capacities ranging from 20 litres to 2000 litres.
About Alkem Laboratories Limited:
Established in 1973 and headquartered in Mumbai, Alkem (NSE: ALKEM, BSE: 539523, Bloomberg: ALKEM.IN, Reuters: ALKE.NS) is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The Company produces branded generics, generic drugs, active pharmaceutical ingredients (APIs) and nutraceuticals, which it markets in India and International markets. With a portfolio of more than 800 brands in India, Alkem is ranked the fifth largest pharmaceutical company in India in terms of domestic sales (Source: IQVIA data March 2022). The company also has presence in more than 40 international markets, with the United States being its key focus market.
Media Contacts:
Veritas Reputation PR | Veritas Reputation PR |
Abhishek Savant 8108848822 abhishek@veritasreputation.com |
Sonali Pandey 9619689679 sonali.pandey@veritasreputation.com |
Fueled by our continuous innovation and armed with EnzeneX™, our fully-integrated CDMO solutions and our biosimilars pipeline are designed to help bring your biologics innovations to life.